Sign in Subscribe
Cervical cancer

Ghana's HPV Vaccination Program: A Medical Imperative and a Public Health Success

Strategic Insights

— 2 min read

Ghana's Human Papillomavirus (HPV) vaccination program has sparked questions among the public, particularly with regards to the inclusion of girls and boys aged 9 to 14 years. The foundation of this program lies in understanding HPV and its relationship with cervical cancer, a leading cause of cancer-related deaths among women in Ghana. The key to this program's success lies in targeting younger girls and boys, who are biologically more susceptible to HPV infection, before they reach sexual maturity.

Key Takeaways:

  • The Human Papillomavirus (HPV) is the most common viral infection of the reproductive tract, spreading mainly through sexual contact and infecting both males and females.
  • High-risk types of HPV, such as HPV 16 and 18, can persist and cause cervical cancer, a leading cause of cancer-related deaths among women in Ghana.
  • The transformation zone, where normal cervical cells are most likely to undergo cancerous changes following persistent HPV infection, is more exposed in younger girls, making them biologically more susceptible to HPV infection.
  • Vaccinating younger girls and boys at ages 9-14 builds a powerful shield around the vulnerable "door" of the cervix before any potential exposure, ensuring lifelong protection.
  • Children aged 9-14 years produce stronger and longer-lasting immune responses to the HPV vaccine than older adolescents or adults, allowing for more efficient and cost-effective protection against the virus.
  • The HPV vaccine is preventive, not curative, and works best when administered before sexual debut, usually before age 16, to prevent infection and not treat it.
  • Treating cervical cancer is expensive and often inaccessible, particularly for women in rural areas, making prevention through vaccination a more cost-effective and sustainable solution.
  • Targeting 9-14-year-olds is also operationally advantageous as it enables school-based delivery, ensuring accessible and equitable vaccination coverage.

Statistics:

  • 70-90% of cervical cancer cases are caused by high-risk types of HPV (source: World Health Organization)
  • The HPV vaccine is 90-100% effective in preventing cervical cancer (source: World Health Organization)
  • Vaccinating 9-14 year olds requires only two doses of the HPV vaccine, compared to three doses required for older adolescents or adults (source: The Lancet)
  • Ghana has set a target of vaccinating 80% of the eligible population by 2025 to achieve herd immunity and reduce overall virus circulation in the population (source: Ministry of Health, Ghana)

Sources:

  • World Health Organization. (2020). Human papillomavirus (HPV) and cervical cancer.
  • World Health Organization. (2020). HPV Vaccine Safety.
  • The Lancet. (2019). Effectiveness of human papillomavirus vaccination against cervical, anal, penile, vulvar, and oropharyngeal cancer: a systematic review and meta-analysis.
  • Ministry of Health, Ghana. (2020). National Immunization Programme: Human Papillomavirus (HPV) Vaccine.

Read more